DEL-22379

CAS No. 181223-80-3

DEL-22379( DEL22379 | DEL 22379 )

Catalog No. M12782 CAS No. 181223-80-3

A small molecule inhibitor of ERK dimerization with IC50 of 0.5 uM, without affecting ERK phosphorylation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 64 In Stock
2MG 36 In Stock
5MG 57 In Stock
10MG 101 In Stock
25MG 186 In Stock
50MG 303 In Stock
100MG 483 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DEL-22379
  • Note
    Research use only, not for human use.
  • Brief Description
    A small molecule inhibitor of ERK dimerization with IC50 of 0.5 uM, without affecting ERK phosphorylation.
  • Description
    A small molecule inhibitor of ERK dimerization with IC50 of 0.5 uM, without affecting ERK phosphorylation; prevents tumorigenesis by RAS-ERK pathway oncogenes.
  • In Vitro
    DEL-22379 is an ERK dimerization inhibitor. DEL-22379 abolishes EGF-induced co-immunoprecipitation of ectopic ERK2 molecules tagged with hemagglutinin (HA) or FLAG epitopes, with an estimated half-maximal inhibitory concentration (IC50) of ~0.5 μM. DEL-22379 inhibits growth of tumor cells harboring RAS-ERK pathway oncogenes. The biological effects of DEL-22379 are investigated on tumor cells in culture. The cytostatic effects of DEL-22379 are compared to those of the MEK inhibitor PD-0325901 and the ERK kinase inhibitor SCH-772984, as reflected by their half-maximal growth inhibitory concentrations (GI50). Cell lines harboring mutant BRAF are the most sensitive to the three compounds. In comparison, wild-type (WT) cell lines for BRAF and RAS are the most resistant, and RAS mutant cells exhibit a range of sensitivities. In cells showing different oncogenic genotypes, distinct sensitivity to DEL-22379 can not be attributed to variations on its effects on dimerization, because DEL-22379 displays similar dimerization- and cytoplasmic signaling-inhibitory dose responses (IC50 of 150-400 nM) regardless of the genotype.
  • In Vivo
    To test DEL-22379 antitumor effects, some of the aforementioned cell lines are xenografted into nude mice, and tumor growth is monitored after intra-peritoneal administration of DEL-22379 at 15 mg/kg. At such a dose, inhibition of ERK dimerization is evident in liver extracts and in xenografted tumors. DEL-22379 markedly inhibits tumor progression for A375 cells (BRAF mutant).
  • Synonyms
    DEL22379 | DEL 22379
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ERK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    181223-80-3
  • Formula Weight
    444.5255
  • Molecular Formula
    C26H28N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 30 mg/mL
  • SMILES
    O=C(NC1=CC2=C(NC(/C2=C/C3=CNC4=C3C=C(OC)C=C4)=O)C=C1)CCN5CCCCC5
  • Chemical Name
    1-Piperidinepropanamide, N-[2,3-dihydro-3-[(5-methoxy-1H-indol-3-yl)methylene]-2-oxo-1H-indol-5-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Herrero A, et al. Cancer Cell. 2015 Aug 10;28(2):170-82.
molnova catalog
related products
  • CC-90003

    CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM.

  • MK-8353

    MK-8353 (SCH-900353) is a?highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively.

  • Astex ERK inhibitor ...

    Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays.